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Conclusions: In the contemporary era, the presence of baseline LV dysfunction in
patients undergoing primary PCI is a powerful predictor of early and late mortality,
regardless of the extent of coronary artery disease.
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Background: Previous studies have reported varying outcomes in pts with ACS and
non-obstructive CAD. Whether non-obstructive CAD confers the same prognosis in pts
with unstable angina (UA) compared to those with NSTEMI is unknown.
Methods: Of 6,921 pts with ACS undergoing an early invasive strategy in whom
quantitative angiography of the entire coronary artery tree was performed in the ACUITY
trial, those with a maximum stenosis of 50 % in all coronary arteries were defined as
non-obstructive CAD. Baseline features and outcomes through 1-year follow-up in such
pts treated without revascularization were examined according to whether they presented
with UA (CKMB or troponin ) or NSTEMI (CKMB or troponin 	).
Results: Non-obstructive CAD was present in 955 pts (14.4%) treated conservatively;
603 (63.1%) had UA whereas 352 (26.9%) had NSTEMI. Compared to pts with UA, pts
with NSTEMI were paradoxically less likely to require insulin; have hypertension or
hyperlipidemia; have had a prior MI or a previous PTCA; or present with ST-segment
deviation  1mm. Pts with NSTEMI were more likely to present at low to intermediate
TIMI risk. A similar percentage of pts with NSTEMI and UA received aspirin and/or a
thienopyridine on discharge. Pts with NSTEMI were more than twice as likely to die or
have an MI by 1 year than pts with UA, whereas unplanned revascularization was more
common in those with UA (Table).
Conclusions: Among ACS pts with non-obstructive CAD treated conservatively in the
ACUITY trial, despite having fewer cardiovascular risk factors at baseline, similar use of
anti-platelet therapies and requiring fewer revascularization procedures, pts with NSTEMI
were more than twice as likely as those with UA to die or have a MI by 1 year. Novel
approaches are required for pts with NSTEMI and non-obstructive CAD.
One-year clinical outcomes in patients with NSTEMI vs. UA
Outcome NSTEMI UA HR [95% CI] P-value
All-cause death 3.2 (11) 1.8 (10) 1.89 (0.80 - 4.54) 0.14
Myocardial infarction 1.5 (5) 0.2 (1) 8.33 (1.01 - 100.0) 0.02
Death or myocardial
infarction
4.7 (16) 2.0 (11) 2.50 (1.16 - 5.56) 0.01
Unplanned
revascularization
0.3 (1) 1.9 (11) 0.16 (0.02 - 1.20) 0.04
MACE 5.0 (17) 3.5 (20) 1.47 (0.77 - 2.78) 0.25
Value estimates are % (n) determined by Kaplan-Meier methods.
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Background: Among patients with acute ST-segment elevation myocardial infarction-
(STEMI), early generation drug-eluting stents(DES) improve efficacy but not safety
compared with bare metal stents(BMS). Newer generation DES eluting everolimus(EES)
and biolimus A9(BES) have been shown to improve clinical outcomes compared with
early generation DES. However, it remains to be determined whether the benefits of
newer over early generation DES translate into improved safety compared with BMS
among appropriately powered population with STEMI.
Methods: Individual patient data of 2665 patients with STEMI enrolled into two large
scale randomized clinical trials comparing newer generation DES with BMS were pooled:
EXAMINATION randomly assigned 1504 patients to treatment with EES or BMS, and
COMFORTABLE AMI randomly assigned 1161 patients to treatment with BES or BMS.
Random effect models were used to assess differences in clinical outcomes between newer
generation DES and BMS for the pre-specified device-oriented composite of cardiac
death, target-vessel reinfarction and target-lesion revascularization and the patient-
oriented composite of death, reinfarction and any revascularization at one year.
Results: Newer generation DES substantially reduced the risk of the primary device-
oriented composite outcome compared with BMS at one year(RR 0.58, CI 95% 0.43 -
0.79, p 0.0004). Similarly, the risk of the primary patient-oriented composite outcome
was lower with newer generation DES than BMS(RR 0.78, 95% CI 0.63 to 0.96, p0.02).
Differences in favor of newer generation DES were driven by both, a lower risk of repeat
revascularization of the target lesion(RR 0.33, 95% CI 0.20–0.52, p0.0001) and a lower
risk of target-vessel reinfarction(RR 0.36, 95% CI 0.14-0.92, p0.03). Newer generation
DES reduced the risk of acute(RR 0.38, 95% CI 0.17-0.85, p0.02) and overall(within
one year) definite stent thrombosis(RR 0.35, 95% CI 0.16 – 0.75, p0.006) compared
with BMS.
Conclusions: Among patients with STEMI, newer generation DES improved safety and
efficacy compared with BMS throughout one year. It remains to be determined whether
these differences in favor of newer generation DES remain sustained during long-term
follow-up.
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Background: The purpose of this study was to determine safety and efficiency of
one-stage PCI of left main coronary artery (LMCA) and infarct-related left anterior
descending (LAD) or left circumflex (LCX) arteries in ST-elevation myocardial infarction
(STEMI). Even though STEMI guidelines recommend to limit the procedure to infarct-
related artery there are cases when it’s impossible to complete the PCI of the infarct-
related LAD or LCX without affecting LMCA. Appropriateness of one-phase PCI in such
cases needs to be investigated.
Methods: 281 PCI of LMCA were performed during the last 5 years. There were 57
stable and 224 ACS patients among them. LMCA lesion as the reason of ACS was in 19
patients, they were not included into the study. In other 205 cases LAD or LCX were
symptom-related accompanying significant LMCA lesions. The ACS subgroup (205
patients) contained 108 non-ST ACS patients and 97 STEMI patients. These 97 STEMI
patients with LMCA stenosis and infarct-related LAD or LCX were of major interest and
were followed up for 4 years.
Results: LAD was infarct-related in 65% of cases, LCX - in 35%. 7 patients were
admitted with cardiogenic shock. Concomitant RCA lesion was in 60% of cases. Most
procedures were performed using transradial approach (81%), IABP was used in 41% of
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